Jun Inoue

This inventor holds 20 USPTO granted patents, plus 1 CIPO patent and 5 EPO patents, primarily in Pharmaceutical Innovation. Top assignees: Senju Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Chemiphar Co., Ltd.. Active years: 1989-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jun Inoue. Retrieved from https://idiyas.com/inventor/jun-inoue

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 20

% Patents Active = 50.0

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 2.9

ph-index = 4

Forward Citations = 59(Granted Patents)

Location History:

Settsu, JP (1989)
Kobe, JP (1999 - 2015)
Woodland Hills, CA (US) (2012 - 2016)

Company Filing History:

19 out of 229

Senju Pharmaceutical Co., Ltd.

patents

2 out of 263

Mitsubishi Tanabe Pharma Corporation

patents

2 out of 132

Nippon Chemiphar Co., Ltd.

where one patent can have more than one assignee

Years Active: 1989-2016

Loading Chart...

Areas of Expertise:

PPAR Agonist

Ophthalmic Composition

Corneal Sensitivity

Dipeptidyl Aldehyde

Alpha-Ketoamide

Angiogenesis Inhibitor

Cysteine Protease

Medicinal Use

Drug Composition

Pharmaceutical Composition

Cyclic Hemiacetal

Imidazolidinedione

20 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9463185 - Pharmaceutical containing PPAR-delta agonist (2016-10-11),

2. 9096538 - Pharmaceutical comprising PPAR agonist (2015-08-04),

3. 8802705 - Pharmaceutical containing PPAR delta agonist (2014-08-12),

4. 8211450 - Ophthalmic composition (2012-07-03),

5. 8148389 - Pharmaceutical comprising PPAR agonist (2012-04-03),

6. 7956072 - Agent for repairing corneal sensitivity containing amide compound (2011-06-07),

7. 7572833 - Drug composition comprising dipeptidyl aldehyde derivative (2009-08-11),

8. 7491705 - Alpha-ketoamide derivative, and production method and use thereof (2009-02-17),

9. 7485654 - Corneal perception recovery drug containing amide compound (2009-02-03),

10. 7223755 - Hydroxymorpholinone derivative and medicinal use thereof (2007-05-29),

11. 7202274 - Cyclic hemiacetal derivative and use thereof (2007-04-10),

12. 7022738 - α-ketoamide derivative and use thereof (2006-04-04),

13. 6919365 - Imidazolidinedione derivatives and use thereof as drugs (2005-07-19),

14. 6551999 - Angiogenesis inhibitor (2003-04-22),

15. 6423691 - Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytography (2002-07-23),

Title: Spotlight on Jun Inoue: Innovator in Pharmaceutical Innovations

Introduction:

Jun Inoue, a distinguished inventor hailing from Kobe, Japan, has made significant contributions to the field of pharmaceuticals with his inventive spirit and dedication. With an impressive portfolio of 20 patents, Jun Inoue is a trailblazer in developing solutions for ocular diseases such as meibomian gland dysfunction and dry eye.

Latest Patents:

In his latest patents, Jun Inoue has introduced groundbreaking pharmaceutical formulations that leverage PPAR agonists to promote the proliferation of meibomian gland epithelial cells and corneal epithelial cells. These formulations serve as essential agents for treating ocular diseases, offering new hope for patients grappling with conditions like meibomian gland dysfunction and evaporative dry eye.

Career Highlights:

Jun Inoue has left an indelible mark on the pharmaceutical industry through his work with esteemed companies such as Senju Pharmaceutical Co., Ltd. and Mitsubishi Tanabe Pharma Corporation. His innovative approach to drug development has garnered recognition and acclaim, solidifying his status as a visionary in the field.

Collaborations:

Throughout his illustrious career, Jun Inoue has collaborated with esteemed professionals in the pharmaceutical realm, including Mitsuyoshi Azuma and Masayuki Nakamura. These collaborations have been instrumental in realizing cutting-edge solutions that have the potential to revolutionize the treatment of ocular diseases.

Conclusion:

Jun Inoue's relentless pursuit of innovation and his unwavering commitment to enhancing patient care underscore his status as a true luminary in the realm of pharmaceutical inventions. His pioneering work continues to inspire and shape the future of pharmaceutical advancements, setting a high bar for aspiring inventors in the industry.

Profile summary based on public USPTO records.